01 — At a Glance
The Pharma Play Nobody’s Talking About (Except The Board of Directors)
- 52-Week High / Low₹1,595 / ₹1,168
- Q3 FY26 Revenue₹2,392 Cr
- Q3 FY26 PAT₹364 Cr
- Q3 EPS (₹)₹12.86
- Annualised EPS (Q3×4)₹51.44
- Book Value₹293
- Price to Book4.98x
- Dividend Yield0.27%
- Debt / Equity0.17x
- FY25 Full-Year EPS₹29.08
The Setup: IPCA finished Q3 FY26 with ₹2,392 crore revenue (+6.6% YoY), ₹364 crore PAT (+26.7% YoY), and operating margins at a beefy 22%. The company spent ₹181 crore settling a European fine, acquired Unichem Ireland for vertical integration into the US market, and watched margins expand 228 basis points despite zero cost tailwinds. The stock price? Still thinking about 2023. This is what happens when a 75-year-old generics maker becomes disciplined about capital allocation while the rest of pharma chases obesity trends.
02 — Introduction
Welcome to The Least Sexy Pharma Story in India (Which Is Why It Works)
IPCA Laboratories. Founded 1949. Fully integrated. Over 350 formulations. Over 80 APIs. Backward integration into raw materials because “why depend on someone else for margins?” Domestic rank #16 with 2% market share — not sexy, but stable. Pain management is 50%+ of their domestic business. Antimalarials are crashing (because fewer people are getting malaria, what a tragedy). And yet, the company is marching forward with something radical: actual execution.
This quarter: Q3 FY26. Revenue ₹2,392 crore (+6.6% YoY). Consolidated PAT ₹364 crore (+26.7% YoY). Operating margin 22% — a 200-basis-point jump from the prior year. The company is expanding in Europe (where pricing isn’t a “blood bath”), scaling the US through Unichem Labs, fixing manufacturing import alerts at Tarapur and Silvassa, and quietly committing ₹182 crore to build an API facility at Wardha that already went commercial in February 2026. Meanwhile, the stock sits at ₹1,459, having crawled up just 12% over the past 12 months while delivering consistent double-digit operating leverage.
This is not a 10x story. This is a 4–5x story with a dividend tacked on. But for investors who watched Torrent and Divi’s Labs trade at 60+x P/E, IPCA at 35x P/E with 228 basis points of margin expansion and a pipeline of 5 biosimilar candidates beginning to commercialise looks absurdly cheap. Let’s dive into a company that nobody bought at ₹1,200 but everybody will regret not buying at ₹1,500.
Concall Bombshell (Feb 2026): Management stated, “We are more going towards CNS, neurology, cardiology… margin profile… improving significantly.” Translation: they are systematically upgrading the product mix away from antimalarials (low margin) toward specialty therapies (high margin). Nobody noticed. Nobody reported it. The stock did nothing.
03 — Business Model: 350 Formulations + 80 APIs + One Direction
Fully Integrated Means They Control The Entire Story
IPCA manufactures over 350 branded and generic formulations across 18 manufacturing units in India, plus plants in the US (via Unichem Labs), Puerto Rico (biosimilars), and Ireland. They make over 80 APIs themselves — which means when the cost of raw materials goes up, they can absorb it at the intermediate stage. When competitors scream about input costs, IPCA shrugs.
Revenue mix: Domestic formulations ~39%, Export formulations ~21%, Subsidiary sales (Unichem Labs) ~25%, APIs ~14%. The domestic business is 17 marketing divisions strong, focusing on pain management (Zerodol — 8% market share, ₹13 billion in sales), cardiovascular, diabetes, dermatology, and antimalarials. The antimalarial franchise is shrinking in revenue share because malaria rates in India have normalized — which is objectively great for public health and objectively bad for IPCA’s top line, but immensely good for margin because pain management and cardiometabolic drugs carry better pricing power.
The US story is the main attraction. Post-2024 FDA clearance of Silvassa, Ratlam, and Indore facilities, Ipca is commercializing its own generics in the US. Five molecules already marketed, generating ~USD 10–11 million quarterly. Another five to seven expected within 12–15 months. Each molecule is backward-integrated (made in-house), which means the gross margin profile is 60%+ — vastly superior to distribution partnerships. Unichem Labs, acquired in 2023, serves as the US commercialization vehicle. It lost high-margin contract manufacturing in 2024 (margin compression to 8% EBITDA), but management targets recovery to 15% EBITDA in 2–3 years as Ipca’s portfolio ramps and plant utilization rises.
Backward Integration Notes: IPCA’s gross margin expanded 235 basis points YoY to 68.9% in FY25 due to “softening raw material costs” AND improved product mix. But management was explicit in Q3 concall: “It is pure product mix, nothing else.” This is extremely important. Margin expansion is not dependent on commodity cycles — it’s structural mix migration from low-margin antimalarials and institutional tender business to high-margin specialty formulations and proprietary US generics.
Domestic Rank#16Market Share 2%
Pain Management50%+Of Domestic Mix
FDA Clear3/3Facilities (2024)
US Generics5 Live5–7 Coming
💬 Does vertical integration into APIs actually matter in pharma, or is it just a nice-to-have? Share your view!
04 — Financials Overview
Q3 FY26: The Numbers That Nobody’s Talking About
Result type: Quarterly Results | Q3 FY26 EPS: ₹12.86 | Annualised EPS (Q3×4): ₹51.44 | Full-year FY25 EPS: ₹29.08
| Metric (₹ Cr) |
Q3 FY26
Dec 2025 |
Q3 FY25
Dec 2024 |
Q2 FY26
Sep 2025 |
YoY % |
QoQ % |
| Revenue | 2,392 | 2,245 | 2,556 | +6.6% | -6.4% |
| Operating Profit | 533 | 463 | 545 | +15.1% | -2.2% |
| OPM % | 22.3% | 20.6% | 21.3% | +170 bps | +100 bps |
| PAT | 364 | 276 | 281 | +32.0% | +29.5% |
| EPS (₹) | 12.86 | 9.78 | 9.99 | +31.5% | +28.7% |
A Word on EPS Calculation: Screener shows P/E of 35.1x against EPS of ₹35.9 (trailing 12 months). Our annualised Q3 calculation: ₹12.86 × 4 = ₹51.44. This mismatch is because Q3 was a strong quarter (22.3% margin vs. historical 18–20%). The trailing-12-months figure includes weaker Q4 FY25 (when the EU fine was still pending) and Q1 FY26 (a soft quarter for export formulations). By FY26-end, management guidance is ₹51–55 EPS. At ₹1,459 CMP, that’s 26–27x — still not cheap, but reasonable for a company expanding margins 170+ bps YoY with structural product mix tailwinds.
Why The Margin Expansion? Not commodity tailwinds (management was explicit: “Material prices are by and large stable”). It’s three things: (1) mix shift from antimalarials (12% EBITDA margin) to pain/neuro/cardio (25–30% margins); (2) Unichem Labs acquisition (despite current weakness, it’s dilutive but dilution narrows as it ramps); (3) operating leverage as fixed costs spread over growing revenue. If Ipca grows revenue 10–12%, expect EBITDA margin expansion of ~150 basis points “every year” — management confirmed this in the concall.
05 — Valuation Discussion: Fair Value Range
Is 35x P/E Justified Or Just Hype?
Join 10,000+ investors who read this every week.
